Search Results for "vaccine, adult"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for vaccine, adult. Results 261 to 270 of 295 total matches.
See also: MMR II
Voclosporin (Lupkynis) for Lupus Nephritis
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021 (Issue 1631)
mofetil (Cellcept, and
generics) and a corticosteroid for treatment of adults
with active lupus ...
Voclosporin (Lupkynis – Aurinia), an oral calcineurin
inhibitor, has been approved by the FDA for use
in combination with the antimetabolite immunosuppressant
mycophenolate mofetil (Cellcept, and
generics) and a corticosteroid for treatment of adults
with active lupus nephritis. It is the first calcineurin
inhibitor to be approved in the US for this indication.
Tacrolimus (Prograf, and others) and cyclosporine
(Neoral, and others), the other available systemic
calcineurin inhibitors, are approved for prophylaxis of
organ rejection in transplant patients.
Statins and Diabetes Risk
The Medical Letter on Drugs and Therapeutics • Sep 01, 2014 (Issue 1450)
an immune
response that interferes with insulin signaling.2
NEW-ONSET DIABETES RISK — A meta-analysis ...
In 2012, the FDA required manufacturers of HMG-CoA
reductase inhibitors (statins) to add a warning to their
labels about reports of increased blood glucose and
glycosylated hemoglobin (HbA1c) levels. Since then,
several new studies have been published.
Risankizumab (Skyrizi) - An IL-23 Antagonist for Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Dec 26, 2022 (Issue 1666)
of moderately
to severely active Crohn’s disease (CD) in adults.
Risankizumab was approved earlier ...
The injectable interleukin (IL)-23 antagonist
risankizumab-rzaa (Skyrizi – Abbvie) has been
approved by the FDA for treatment of moderately
to severely active Crohn's disease (CD) in adults.
Risankizumab was approved earlier for treatment of
plaque psoriasis and psoriatic arthritis.
Ganciclovir
The Medical Letter on Drugs and Therapeutics • Aug 25, 1989 (Issue 799)
in urine.
The serum elimination half-life is about three hours in adults with normal renal function ...
Ganciclovir sodium (Cytovene - Syntex), a synthetic antiviral nucleoside analog, is now available in the USA for intravenous treatment of cytomegalovirus (CMV) retinitis in immunocompromised patients. CMV retinitis occurs in 20% to 25% of patients with AIDS.
More New Drugs for HIV and Associated Infections
The Medical Letter on Drugs and Therapeutics • Feb 14, 1997 (Issue 994)
one nucleoside (SH Cheeseman et al, J Acquir Immune Defic Syndr, 8:141, 1995).
Clinical Trials ...
Four new drugs have become available in the USA for HIV infection or its complications. Nevirapine (Viramune - Roxane), intravenous cidofovir (Vistide - Gilead), and amphotericin B oral suspension (Fungizone Oral Suspension - Bristol-Myers Squibb) have been approved by the US Food and Drug Administration; nelfinavir (Viracept - Agouron) is currently available only through an "Expanded Access Program."
Treatment of Clostridium Difficile Infection
The Medical Letter on Drugs and Therapeutics • Feb 21, 2011 (Issue 1358)
) is the most common
infectious cause of healthcare-associated diarrhea in
adults. The incidence and severity ...
Clostridium difficile infection (CDI) is the most common infectious cause of healthcare-associated diarrhea in adults. The incidence and severity of CDI have increased in recent years with the emergence of an epidemic virulent strain (NAP1/BI/027). Common risk factors include admission to a healthcare facility, increasing age and severity of underlying illness, gastric acid suppression and exposure to antimicrobials, particularly clindamycin, ampicillin, cephalosporins or fluoroquinolones. Patients who develop CDI while receiving a precipitating antibiotic should have the antibiotic...
Drugs for Bacterial Infections
Treatment Guidelines from The Medical Letter • Jul 01, 2013 (Issue 131)
aerobic
Table 1. Some Oral Antibacterial Drugs
Some Available Usual Usual
Drug Formulations Adult ...
The text that follows reviews some common bacterial
infections and their empiric treatment pending the
results of culture and susceptibility testing. The recommendations
made here are based on the results of
susceptibility studies, clinical trials, and the opinions
of Medical Letter reviewers. Tables 1 and 2 list the usual
dosages of antibacterial drugs.
Drugs for HIV Infection
Treatment Guidelines from The Medical Letter • Feb 01, 2014 (Issue 138)
as initial HIV-1 therapy in adults. J Acquir
Immune Defic Syndr 2009; 50:367.
21. M Markowitz et al. Rapid ...
Antiretroviral therapy is recommended for all HIV-infected
patients, both to reduce the risk of disease
progression and to prevent transmission of the virus to
others. Various guidelines for treatment of HIV infection
are available.
Botulinum Toxin (Botox Cosmetic) for Frown Lines
The Medical Letter on Drugs and Therapeutics • May 27, 2002 (Issue 1131)
of glabellar ("frown") lines in adults not more than 65 years old, and is
being heavily advertised. Even ...
Botulinum toxin type A (Botox Cosmetic - Allergan) has received formal approval from the FDA for treatment of glabellar ("frown") lines in adults not more than 65 years old, and is being heavily advertised. Even before this approval, cosmetic use of botulinum toxin to reduce wrinkles on the face and neck had become a popular alternative to cosmetic surgery (Medical Letter 1999; 41:63). Botulinum toxin type A (Botox) and type B (Myobloc) are approved for treatment of cervical dystonia (Medical Letter 2001; 43:53), and type A has been approved since 1989 for treatment of strabismus and...
Jentadueto XR for Type 2 Diabetes
The Medical Letter on Drugs and Therapeutics • Aug 01, 2016 (Issue 1500)
and Components
Drug Some Available Formulations Usual Adult Dosage Cost1
DPP-4 Inhibitor/Metformin Combinations ...
The FDA has approved Jentadueto XR (Boehringer
Ingelheim/Lilly), a once-daily extended-release formulation
of the dipeptidyl peptidase-4 (DPP-4) inhibitor
linagliptin and the biguanide metformin, for oral
treatment of type 2 diabetes. Linagliptin and metformin
have been available for years in a twice-daily immediate-release combination (Jentadueto). Once-daily
extended-release formulations combining metformin
with the DPP-4 inhibitors saxagliptin (Kombiglyze XR)
and sitagliptin (Janumet XR) are also available.